Antibody-targeted thrombolytic agents.
Plasminogen activator therapy for acute myocardial infarction has become standard medical practice. Bleeding complications, however, limit the utility of the currently available agents. This article reviews how the tools of immunology, molecular biology and protein engineering are being used to develop safer and more effective plasminogen activators.
Haber
E
E
Cardiac Unit, Massachusetts General Hospital, Boston 02114.
Quertermous
T
T
Matsueda
G R
GR
Runge
M S
MS
Bode
C
C
D005342:Fibrinolysis / Q000276:immunology; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000276:immunology; D010960:Plasminogen Activators / Q000627:therapeutic use*; D011487:Protein Conformation; D011994:Recombinant Proteins / Q000627:therapeutic use; D015912:Thrombolytic Therapy
D011994:Recombinant Proteins; D010960:Plasminogen Activators